Ad
related to: hemophilia a clinical guidelines- Patient Resources
Find helpful resources and videos
for rare bleeding disorders.
- Hemophilia A Information
Learn about hemophilia A.
View important disease details.
- Family Planning Info
Bleeding disorders and pregnancy.
Steps to take before pregnancy.
- Active Lifestyle Benefits
Why moving more is a good move.
Bleeding disorders and exercise.
- Patient Resources
Search results
Results from the WOW.Com Content Network
Hemophilia A: Protein structure of coagulation factor VIII, of which its deficiency is the cause of haemophilia A. Specialty: Haematology: Symptoms: Prolonged bleeding from common injuries [1] Causes: Factor VIII deficiency [2] Diagnostic method: Bleeding time, [2] coagulation screen, genetic testing: Prevention: Hepatitis B vaccine should be ...
Acquired haemophilia A (AHA) is a rare but potentially life-threatening bleeding disorder characterized by autoantibodies directed against coagulation factor VIII.These autoantibodies constitute the most common spontaneous inhibitor to any coagulation factor and may induce spontaneous bleeding in patients with no previous history of a bleeding disorder.
Efmoroctocog alfa, sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A. [5] [6] [7] Efmoroctocog alfa is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). [5]
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.
Haemophilia (British English), or hemophilia (American English) [6] (from Ancient Greek αἷμα (haîma) 'blood' and φιλία (philía) 'love of'), [7] is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.
Alnylam's program in hemophilia comprises part of its 'Alnylam 5x15' product strategy, by which the company aims to advance five programs in clinical development, including programs in advanced ...
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). [4]
Ad
related to: hemophilia a clinical guidelines